Epratuzumab Shows Promise for Lupus in Clinical Study

MedPage Today reports:

In a phase IIb, randomized, controlled study, treatment with epratuzumab, a CD22-targeted monoclonal antibody, was well tolerated without an increase in serious adverse events compared with placebo in patients with moderately to severely active SLE. Treatment appeared to be associated with improvements in disease activity compared with placebo. Initial clinical studies of epratuzumab in patients with active, moderate-to-severe systemic lupus erythematosus (SLE) are suggesting promise for this monoclonal antibody.